trending Market Intelligence /marketintelligence/en/news-insights/trending/b2azmtibdnjmlvp4mqplwq2 content esgSubNav
In This List

Dimerix names 1st chief medical officer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dimerix names 1st chief medical officer

Dimerix Ltd. named David Packham to the newly created position of chief medical officer.

Packham was a principal investigator on Dimerix's phase 2a trial of DMX-200 in chronic kidney disease that successfully concluded in 2017, the company said.

Packham is also director of the Melbourne Renal Research Group, a specialist research facility for nephrology studies. He will lead Melbourne-based Dimerix's development efforts for DMX-200.